Xolair omalizumab regulatory update

FDA approved an sBLA from Roche’s Genentech unit for Xolair omalizumab to treat moderate to severe persistent asthma inadequately controlled with inhaled corticosteroids to include patients ages 6-11. The recombinant humanized mAb against IgE is approved in the U.S. in patients ages >=12 for the indication and to treat chronic idiopathic urticaria. ...